InflaRx (NASDAQ:IFRX) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of InflaRx (NASDAQ:IFRX) in a report released on Tuesday, Marketbeat reports. The firm issued a buy rating and a $6.00 price target on the stock.

A number of other analysts have also issued reports on IFRX. Oppenheimer dropped their target price on InflaRx from $6.00 to $3.00 and set an “outperform” rating on the stock in a research report on Thursday, May 29th. Raymond James Financial lowered InflaRx from a “strong-buy” rating to an “outperform” rating and set a $2.00 target price on the stock. in a research report on Thursday, May 29th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, InflaRx currently has a consensus rating of “Buy” and an average target price of $6.20.

InflaRx Stock Performance

Shares of NASDAQ IFRX opened at $1.75 on Tuesday. InflaRx has a 1 year low of $0.71 and a 1 year high of $2.82. The firm has a market cap of $117.48 million, a price-to-earnings ratio of -2.19 and a beta of 1.43. The stock’s 50-day simple moving average is $0.91 and its 200-day simple moving average is $1.14.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.24). The business had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.02 million. As a group, research analysts predict that InflaRx will post -1.04 EPS for the current year.

Institutional Trading of InflaRx

Several hedge funds and other institutional investors have recently bought and sold shares of IFRX. Northern Trust Corp increased its holdings in InflaRx by 1,933.1% in the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company’s stock valued at $1,647,000 after buying an additional 634,045 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of InflaRx during the fourth quarter valued at approximately $55,000. XTX Topco Ltd bought a new position in shares of InflaRx during the first quarter valued at approximately $38,000. DAFNA Capital Management LLC bought a new position in shares of InflaRx during the first quarter valued at approximately $459,000. Finally, 683 Capital Management LLC grew its holdings in shares of InflaRx by 26.8% during the first quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock valued at $2,678,000 after purchasing an additional 555,000 shares during the last quarter. 42.39% of the stock is owned by institutional investors.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.